Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 14c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q1 EPS of ($0.78), $0.14 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $35 million versus the consensus estimate of $33.65 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• AeroVironment restates quarterly financials, citing $89M goodwill error